The cell cycle and drug discovery: the promise and the hope.

In recent years, there have been major developments in the understanding of the cell cycle. It is now known that normal cellular proliferation is tightly regulated by the activation and deactivation of a series of proteins that constitute the cell cycle machinery. The expression and activity of components of the cell cycle can be altered during the development of a variety of diseases where aberrant proliferation contributes to the pathology of the illness. Apart from yielding a new source of untapped therapeutic targets, it is likely that manipulating the activity of such proteins in diseased states will provide an important route for treating proliferative disorders, and the opportunity to develop a novel class of future medicines.

[1]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Jansen-Dürr How viral oncogenes make the cell cycle. , 1996, Trends in genetics : TIG.

[3]  G. Vassal,et al.  Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. , 1998, Biochimie.

[4]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[6]  N. Dyson The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[7]  P. Guldberg,et al.  Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb , 1998, Leukemia.

[8]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[9]  K. Vousden Regulation of the cell cycle by viral oncoproteins. , 1995, Seminars in cancer biology.

[10]  E J Topol,et al.  Local drug delivery for the prevention of restenosis. Fact, fancy, and future. , 1994, Circulation.

[11]  C. Conti,et al.  Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation , 1999, Oncogene.

[12]  G. Brooks,et al.  Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? , 1999, European heart journal.

[13]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[16]  A. Cribier,et al.  Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. , 1998, Journal of the American College of Cardiology.

[17]  A. Hengstermann,et al.  Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.

[18]  E. Lakatta,et al.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. , 1995, The Journal of clinical investigation.

[19]  W. Zwerschke,et al.  Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. , 1996, Oncogene.

[20]  L. Meijer,et al.  The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. , 1997, Experimental cell research.

[21]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[22]  T. Jacks,et al.  Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1 , 1996, Cell.

[23]  Y. Furukawa,et al.  Over‐expression and amplification of the CDC2 gene in leukaemia cells , 1995, British journal of haematology.

[24]  K. Münger,et al.  The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. , 1997, Genes & development.

[25]  N. Matsubara,et al.  Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. , 1997, Cancer research.

[26]  J. Nevins,et al.  Toward an understanding of the functional complexity of the E2F and retinoblastoma families. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  P. Nurse,et al.  Animal cell cycles and their control. , 1992, Annual review of biochemistry.

[28]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[29]  J. Graybill The future of antifungal therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  T. Jacobs,et al.  Cell Cycle Control , 1995 .

[31]  A. Levitzki,et al.  Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. , 1998, Experimental cell research.

[32]  R. Buckle,et al.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.

[33]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[34]  Y. Chen,et al.  Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. , 1991, Oncogene.

[35]  A. Levitzki Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  G. Stamp,et al.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.

[37]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[38]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[39]  N. L. Thangue,et al.  DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. , 1994 .

[40]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[41]  P. Nurse Checkpoint Pathways Come of Age , 1997, Cell.

[42]  N. L. Thangue,et al.  Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor , 1997, Nature Biotechnology.

[43]  B. Nickoloff,et al.  Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. , 1999, Journal of dermatological science.

[44]  P. Tsao,et al.  Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. , 1997, The Journal of clinical investigation.

[45]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[46]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[47]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[48]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[49]  A. Levitzki,et al.  Tyrphostin AG 494 blocks Cdk2 activation , 1997, FEBS letters.

[50]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[51]  E. White,et al.  Life, death, and the pursuit of apoptosis. , 1996, Genes & development.

[52]  Y. Kaneda,et al.  Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. , 1998, Circulation research.

[53]  E. Nabel,et al.  Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.

[54]  Jian-Mei Li,et al.  Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. , 1998, Cardiovascular research.

[55]  A. Bradley,et al.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.

[56]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Wall,et al.  Camptothecin and taxol: Discovery to clinic , 1998, Medicinal research reviews.

[58]  D. Schrijvers,et al.  Update on the taxoids and other new agents in head and neck cancer therapy. , 1998, Current opinion in oncology.

[59]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases , 1997 .

[60]  K. Vousden,et al.  Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.

[61]  M. Aoki,et al.  Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide , 1997, Nature Medicine.

[62]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[63]  G. Bevilacqua,et al.  Cyclin‐D1 expression in node‐positive (N+) and node‐negative (N−) infiltrating human mammary carcinomas , 1999, International journal of cancer.

[64]  P. Tsao,et al.  Genetic engineering of vein grafts resistant to atherosclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Morris Molecular clocks: Defusing the Cambrian ‘explosion’? , 1997, Current Biology.

[66]  P. V. van Diest,et al.  Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.

[67]  N. Kashihara,et al.  Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. , 1998, The Journal of clinical investigation.

[68]  T. Ogihara,et al.  Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.

[69]  E. Fearon Human cancer syndromes: clues to the origin and nature of cancer. , 1997, Science.

[70]  Anthony R. Hall,et al.  p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.

[71]  K. Kinzler,et al.  Sequence-specific transcriptional activation is essential for growth suppression by p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[72]  N. L. La Thangue,et al.  A new component of the transcription factor DRTF1/E2F , 1993, Nature.

[73]  Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.

[74]  M. Greenberg,et al.  E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation , 1996, Cell.

[75]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[76]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[77]  J. Gabrilove,et al.  The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. , 1997, Blood.

[78]  H. Hausen Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .

[79]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[80]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[81]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[82]  J. Pines,et al.  Cyclins and cyclin-dependent kinases: take your partners , 1993 .

[83]  B. Stillman,et al.  Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. , 1997, Genes & development.

[84]  J. Leiden,et al.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.

[85]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[86]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.